Alina Denham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alina Denham has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Elaine L. Hill
Department of Public Health Sciences, University of Rochester, Rochester, NY, USA
4 shared publications Peter J. Veazie
Department of Public Health Sciences, School of Medicine and Dentistry, University of Rochester, Rochester, USA
2 shared publications- Adit Anand
Department of Biomedical Informatics, Columbia University Irving Medical Center CUIMC , 622 West 168th St, PH-20 , New York, NY 10032
1 shared publication - Amin Manna
Palantir Technologies , Denver, Colorado, USA
1 shared publication - Andrew E. Williams
(17)Tufts University
1 shared publication - Andrew J. Boslett
Department of Public Health Sciences, School of Medicine and Dentistry University of Rochester Rochester NY, USA
1 shared publication
Latest Publications
- 18 September 2026
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 88 (4) , 540-541
In reply
- 18 September 2026
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 88 (4) , 540-541
In reply
- 24 March 2026
- Published by Elsevier in Annals of Emergency Medicine
Urgent Care and Emergency Department Visitors: A Latent Class Analysis
- 24 March 2026
- Published by Elsevier in Annals of Emergency Medicine
Urgent Care and Emergency Department Visitors: A Latent Class Analysis
- 9 December 2025
- Published by Wiley in Health Services Research
- Vol. 61 (1) , e70069
In Memoriam: Professor Peter J. Veazie (1963–2025)
- 9 December 2025
- Published by Wiley in Health Services Research
- Vol. 61 (1) , e70069
In Memoriam: Professor Peter J. Veazie (1963–2025)
- Open Access
- 23 October 2023
- Published by Cambridge University Press (CUP) in Health Economics, Policy and Law
- Vol. 19 (1) , 73-91
Is the emergency department used as a substitute or a complement to primary care in Medicaid?
Policies to decrease low-acuity emergency department (ED) use have traditionally assumed that EDs are a substitute for unavailable primary care (PC). However, such policies can exacerbate ED overcrowding, rather than ameliorate it, if patients use EDs to complement, rather than substitute, their PC use. We tested whether Medicaid managed care enrolees visit the ED for nonemergent and PC treatable conditions to substitute for or to complement PC. Based on consumer choice theory, we modelled county-level monthly ED visit rate as a function of PC supply and used 2012–2015 New York Statewide Planning and Research Cooperative System (SPARCS) outpatient data and non-linear least squares method to test substitution vs complementarity. In the post-Medicaid expansion period (2014–2015), ED and PC are substitutes state-wide, but are complements in highly urban and poorer counties during nights and weekends. There is no evidence of complementarity before the expansion (2012–2013). Analyses by PC provider demonstrate that the relationship between ED and PC differs depending on whether PC is provided by physicians or advanced practice providers. Policies to reduce low-acuity ED use via improved PC access in Medicaid are likely to be most effective if they focus on increasing actual appointment availability, ideally by physicians, in areas with low PC provider supply. Different aspects of PC access may be differently related to low-acuity ED use.
- 23 October 2023
- Published by Cambridge University Press (CUP) in Health Economics, Policy and Law
- Vol. 19 (1) , 73-91
Open AccessIs the emergency department used as a substitute or a complement to primary care in Medicaid?
Policies to decrease low-acuity emergency department (ED) use have traditionally assumed that EDs are a substitute for unavailable primary care (PC). However, such policies can exacerbate ED overcrowding, rather than ameliorate it, if patients use EDs to complement, rather than substitute, their PC use. We tested whether Medicaid managed care enrolees visit the ED for nonemergent and PC treatable conditions to substitute for or to complement PC. Based on consumer choice theory, we modelled county-level monthly ED visit rate as a function of PC supply and used 2012–2015 New York Statewide Planning and Research Cooperative System (SPARCS) outpatient data and non-linear least squares method to test substitution vs complementarity. In the post-Medicaid expansion period (2014–2015), ED and PC are substitutes state-wide, but are complements in highly urban and poorer counties during nights and weekends. There is no evidence of complementarity before the expansion (2012–2013). Analyses by PC provider demonstrate that the relationship between ED and PC differs depending on whether PC is provided by physicians or advanced practice providers. Policies to reduce low-acuity ED use via improved PC access in Medicaid are likely to be most effective if they focus on increasing actual appointment availability, ideally by physicians, in areas with low PC provider supply. Different aspects of PC access may be differently related to low-acuity ED use.
- 1 July 2021
- Published by Elsevier in Social Science & Medicine
- Vol. 281, 114113
Understanding how psychosocial factors relate to seeking medical care among older adults using a new model of care seeking
- 1 July 2021
- Published by Elsevier in Social Science & Medicine
- Vol. 281, 114113
Understanding how psychosocial factors relate to seeking medical care among older adults using a new model of care seeking
- 1 April 2021
- Published by Elsevier in Environmental Research
- Vol. 195, 110872
Acute myocardial infarction associated with unconventional natural gas development: A natural experiment
- 1 April 2021
- Published by Elsevier in Environmental Research
- Vol. 195, 110872
Acute myocardial infarction associated with unconventional natural gas development: A natural experiment
- Open Access
The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction
Background The majority of U.S. reports of COVID-19 clinical characteristics, disease course, and treatments are from single health systems or focused on one domain. Here we report the creation of the National COVID Cohort Collaborative (N3C), a centralized, harmonized, high-granularity electronic health record repository that is the largest, most representative U.S. cohort of COVID-19 cases and controls to date. This multi-center dataset supports robust evidence-based development of predictive and diagnostic tools and informs critical care and policy. Methods and Findings In a retrospective cohort study of 1,926,526 patients from 34 medical centers nationwide, we stratified patients using a World Health Organization COVID-19 severity scale and demographics; we then evaluated differences between groups over time using multivariable logistic regression. We established vital signs and laboratory values among COVID-19 patients with different severities, providing the foundation for predictive analytics. The cohort included 174,568 adults with severe acute respiratory syndrome associated with SARS-CoV-2 (PCR >99% or antigen Conclusions This is the first description of an ongoing longitudinal observational study of patients seen in diverse clinical settings and geographical regions and is the largest COVID-19 cohort in the United States. Such data are the foundation for ML models that can be the basis for generalizable clinical decision support tools. The N3C Data Enclave is unique in providing transparent, reproducible, easily shared, versioned, and fully auditable data and analytic provenance for national-scale patient-level EHR data. The N3C is built for intensive ML analyses by academic, industry, and citizen scientists internationally. Many observational correlations can inform trial designs and care guidelines for this new disease.
Open AccessThe National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction
Background The majority of U.S. reports of COVID-19 clinical characteristics, disease course, and treatments are from single health systems or focused on one domain. Here we report the creation of the National COVID Cohort Collaborative (N3C), a centralized, harmonized, high-granularity electronic health record repository that is the largest, most representative U.S. cohort of COVID-19 cases and controls to date. This multi-center dataset supports robust evidence-based development of predictive and diagnostic tools and informs critical care and policy. Methods and Findings In a retrospective cohort study of 1,926,526 patients from 34 medical centers nationwide, we stratified patients using a World Health Organization COVID-19 severity scale and demographics; we then evaluated differences between groups over time using multivariable logistic regression. We established vital signs and laboratory values among COVID-19 patients with different severities, providing the foundation for predictive analytics. The cohort included 174,568 adults with severe acute respiratory syndrome associated with SARS-CoV-2 (PCR >99% or antigen Conclusions This is the first description of an ongoing longitudinal observational study of patients seen in diverse clinical settings and geographical regions and is the largest COVID-19 cohort in the United States. Such data are the foundation for ML models that can be the basis for generalizable clinical decision support tools. The N3C Data Enclave is unique in providing transparent, reproducible, easily shared, versioned, and fully auditable data and analytic provenance for national-scale patient-level EHR data. The N3C is built for intensive ML analyses by academic, industry, and citizen scientists internationally. Many observational correlations can inform trial designs and care guidelines for this new disease.
Using contributing causes of death improves prediction of opioid involvement in unclassified drug overdoses in US death records
Background and Aims: A substantial share of fatal drug overdoses is missing information on specific drug involvement, leading to under‐reporting of opioid‐related death rates and a misrepresentation of the extent of the opioid epidemic. We aimed to compare methodological approaches to predicting opioid involvement in unclassified drug overdoses in US death records and to estimate the number of fatal opioid overdoses from 1999 to 2016 using the best‐performing method. Design: This was a secondary data analysis of the universe of drug overdoses in 1999–2016 obtained from the National Center for Health Statistics Detailed Multiple Cause of Death records. Setting: United States. Cases: A total of 632 331 drug overdose decedents. Drug overdoses with known drug classification comprised 78.2% of the cases ( n = 494 316) and unclassified drug overdoses (ICD‐10 T50.9) comprised 21.8% ( n = 138 015). Measurements: Known opioid involvement was defined using ICD‐10 codes T40.0–40.4 and T40.6, recorded in the set of contributing causes. Opioid involvement in unclassified drug overdoses was predicted using multiple methodological approaches: logistic regression and machine learning techniques, inclusion/exclusion of contributing causes of death and inclusion/exclusion of county‐level characteristics. Having selected the model with the highest predictive ability, we calculated corrected estimates of opioid‐related mortality. Findings: Logistic regression and random forest models performed similarly. Including contributing causes substantially improved predictive accuracy, while including county characteristics did not. Using a superior prediction model, we found that 71.8% of unclassified drug overdoses in 1999–2016 involved opioids, translating into 99 160 additional opioid‐related deaths, or approximately 28% more than reported. Importantly, there was a striking geographic variation in undercounting of opioid overdoses. Conclusions: In modeling opioid involvement in unclassified drug overdoses, highest predictive accuracy is achieved using a statistical model—either logistic regression or a random forest ensemble—with decedent characteristics and contributing causes of death as predictors.
Using contributing causes of death improves prediction of opioid involvement in unclassified drug overdoses in US death records
Background and Aims: A substantial share of fatal drug overdoses is missing information on specific drug involvement, leading to under‐reporting of opioid‐related death rates and a misrepresentation of the extent of the opioid epidemic. We aimed to compare methodological approaches to predicting opioid involvement in unclassified drug overdoses in US death records and to estimate the number of fatal opioid overdoses from 1999 to 2016 using the best‐performing method. Design: This was a secondary data analysis of the universe of drug overdoses in 1999–2016 obtained from the National Center for Health Statistics Detailed Multiple Cause of Death records. Setting: United States. Cases: A total of 632 331 drug overdose decedents. Drug overdoses with known drug classification comprised 78.2% of the cases ( n = 494 316) and unclassified drug overdoses (ICD‐10 T50.9) comprised 21.8% ( n = 138 015). Measurements: Known opioid involvement was defined using ICD‐10 codes T40.0–40.4 and T40.6, recorded in the set of contributing causes. Opioid involvement in unclassified drug overdoses was predicted using multiple methodological approaches: logistic regression and machine learning techniques, inclusion/exclusion of contributing causes of death and inclusion/exclusion of county‐level characteristics. Having selected the model with the highest predictive ability, we calculated corrected estimates of opioid‐related mortality. Findings: Logistic regression and random forest models performed similarly. Including contributing causes substantially improved predictive accuracy, while including county characteristics did not. Using a superior prediction model, we found that 71.8% of unclassified drug overdoses in 1999–2016 involved opioids, translating into 99 160 additional opioid‐related deaths, or approximately 28% more than reported. Importantly, there was a striking geographic variation in undercounting of opioid overdoses. Conclusions: In modeling opioid involvement in unclassified drug overdoses, highest predictive accuracy is achieved using a statistical model—either logistic regression or a random forest ensemble—with decedent characteristics and contributing causes of death as predictors.
- 1 March 2019
- Vol. 25 (3) , 129-+
Did Medicaid Expansion Matter in States With Generous Medicaid?
OBJECTIVES: It is unclear whether the Medicaid expansion under the Affordable Care Act had an effect on coverage in states with relatively generous pre-expansion Medicaid eligibility levels. We examined the effect of the Medicaid expansions on Medicaid coverage in 4 generous states: New York, Vermont, Massachusetts, and Delaware. STUDY DESIGN: We used the American Community Survey (2011-2016) to estimate effects on coverage among nonelderly adults with incomes up to 138% of the federal poverty level. METHODS: We estimated differences in differences (DID) in marginal probabilities following probit models, comparing New York, Vermont, Massachusetts, and Delaware with nonexpansion states on the East Coast. RESULTS: There is strong evidence of the effect in New York: DID estimates ranged from 3.3 to 5.2 percentage points. There is weak or no evidence of coverage gains in the other 3 states. Pronounced effects were found among the racial/ethnic majority (white, non-Hispanic white, and nonblack populations) in New York, as well as the working poor and previously eligible in New York and Massachusetts. CONCLUSIONS: Even in states with relatively generous pre-expansion Medicaid programs, the expansion can produce nontrivial coverage gains, as evidenced by New York. Our findings of spillover effects may indicate the relative importance and success of a simplified enrollment process and increased media coverage in boosting enrollment in Medicaid. Our subgroup analyses highlight a potential need to improve access to office-based care to accommodate the growing population of the working poor on Medicaid and potential changes in the Medicaid risk pool served by managed care organizations and subsequent decreases in capitated payments.
- 1 March 2019
- Vol. 25 (3) , 129-+
Did Medicaid Expansion Matter in States With Generous Medicaid?
OBJECTIVES: It is unclear whether the Medicaid expansion under the Affordable Care Act had an effect on coverage in states with relatively generous pre-expansion Medicaid eligibility levels. We examined the effect of the Medicaid expansions on Medicaid coverage in 4 generous states: New York, Vermont, Massachusetts, and Delaware. STUDY DESIGN: We used the American Community Survey (2011-2016) to estimate effects on coverage among nonelderly adults with incomes up to 138% of the federal poverty level. METHODS: We estimated differences in differences (DID) in marginal probabilities following probit models, comparing New York, Vermont, Massachusetts, and Delaware with nonexpansion states on the East Coast. RESULTS: There is strong evidence of the effect in New York: DID estimates ranged from 3.3 to 5.2 percentage points. There is weak or no evidence of coverage gains in the other 3 states. Pronounced effects were found among the racial/ethnic majority (white, non-Hispanic white, and nonblack populations) in New York, as well as the working poor and previously eligible in New York and Massachusetts. CONCLUSIONS: Even in states with relatively generous pre-expansion Medicaid programs, the expansion can produce nontrivial coverage gains, as evidenced by New York. Our findings of spillover effects may indicate the relative importance and success of a simplified enrollment process and increased media coverage in boosting enrollment in Medicaid. Our subgroup analyses highlight a potential need to improve access to office-based care to accommodate the growing population of the working poor on Medicaid and potential changes in the Medicaid risk pool served by managed care organizations and subsequent decreases in capitated payments.